
Jan 23 (Reuters) - Immunitybio Inc IBRX.O:
IMMUNITYBIO REPORTS MEDIAN OVERALL SURVIVAL NOT YET REACHED AND LYMPHOPENIA REVERSED IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING ANKTIVA® PLUS CAR-NK, CHEMO-FREE THERAPY
IMMUNITYBIO INC: THREE PARTICIPANTS EXPERIENCED SERIOUS ADVERSE EVENTS SUSPECTED TO BE RELATED TO EXPERIMENTAL THERAPY
IMMUNITYBIO INC: TREATMENT REGIMEN DEMONSTRATED A MANAGEABLE SAFETY PROFILE